This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years

This study is not yet open for participant recruitment.
See Contacts and Locations
Verified June 2017 by Kyowa Kirin Pharmaceutical Development Ltd
Sponsor:
Information provided by (Responsible Party):
Kyowa Kirin Pharmaceutical Development Ltd
ClinicalTrials.gov Identifier:
NCT01596413
First received: April 26, 2012
Last updated: June 7, 2017
Last verified: June 2017
  Purpose
The purpose of this study is to determine the dosing strategy for adolescents aged 6 to 12 years.

Condition Intervention Phase
Chemotherapy Induced Nausea and Vomiting Drug: Sancuso Drug: IV granisetron Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: An Open-label, Cross-over, Pharmacokinetic Study to Assess the Safety and Pharmacokinetics of Transdermal Granisetron (Sancuso® Patch) and IV Granisetron in a Pediatric Oncology Population (Aged 6 to 12 Years)

Resource links provided by NLM:


Further study details as provided by Kyowa Kirin Pharmaceutical Development Ltd:

Primary Outcome Measures:
  • Plasma concentration [ Time Frame: Up to 7 days ]
    Analysis of the plasma concentration of Intravenous granisetron vs transdermal granisetron in pediatric patients receiving chemotherapy over two sequential cycles.


Secondary Outcome Measures:
  • Safety [ Time Frame: Up to 7 days ]
    Safety: based on medical review of adverse event reports and the results of vital sign measurements, electrocardiograms (ECGs)


Estimated Enrollment: 16
Arms Assigned Interventions
Experimental: Sancuso Arm
patch
Drug: Sancuso
granisetron transdermal system
Active Comparator: IV Granisetron
IV
Drug: IV granisetron
IV
Other Name: IV

  Eligibility

Ages Eligible for Study:   6 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. 6 to 12 years of age inclusive at screening.
  2. Written patient or parental (or appropriate legal representative) IRB approved informed consent as appropriate.
  3. Written patient assent (as appropriate).
  4. Confirmed malignancy.
  5. Scheduled to receive 2 or more cycles* of emetogenic chemotherapy requiring 5-HT3 antagonist treatment.
  6. Scheduled to receive one or more consecutive days of 5-HT3 antagonist treatment, per cycle, as CINV prophylaxis.

    • The cycles of chemotherapy must be consecutive (i.e. one followed by the other) but do not have to be the first and second cycle of a line of treatment.

Exclusion Criteria:

  1. Hypersensitivities, allergies or contraindications to study medications; intolerance of medical tape or sticking plaster.
  2. Clinical or laboratory signs and symptoms of significant cerebral, cardiovascular, respiratory, renal, hepatobiliary, pancreatic or infectious disease, which in the Investigator's judgment may interfere with the study assessment or completion of the study.
  3. Patients with a known history or predisposition to cardiac conduction interval abnormalities, including QT Syndrome, or known family history of long QT Syndrome or taking medications that are known to prolong the QT interval.
  4. Patients scheduled to have routine surgery during the study duration.
  5. Patients with a life expectancy of < 6 months.
  6. Scarring or significant skin disease on both upper arms.
  7. Female patients who are pregnant or breast-feeding. All post menarche female patients must have a pregnancy test at screening.
  8. Patients who are known or thought to be sexually active must use effective birth control.**
  9. Administration of other investigational drugs within 30 days preceding the screening visit, except for anticancer treatments.
  10. Any conditions associated with non-compliance.

    • Effective birth control includes absolute abstinence or double barrier birth control methods i.e. condom and one of the following: combined oral contraceptive, diaphragm, depot contraceptive injection.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01596413

Contacts
Contact: Alexandre Andre +44 (0) 1896 664000 alexandre.andre@kyowakirin.com

Sponsors and Collaborators
Kyowa Kirin Pharmaceutical Development Ltd
  More Information

Responsible Party: Kyowa Kirin Pharmaceutical Development Ltd
ClinicalTrials.gov Identifier: NCT01596413     History of Changes
Other Study ID Numbers: 392MD/46/C
Study First Received: April 26, 2012
Last Updated: June 7, 2017

Keywords provided by Kyowa Kirin Pharmaceutical Development Ltd:
CINV

Additional relevant MeSH terms:
Vomiting
Signs and Symptoms, Digestive
Signs and Symptoms
Granisetron
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on June 26, 2017